These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

118 related articles for article (PubMed ID: 29500352)

  • 1. Concurrent miR-21 suppression and FXR activation as a mechanism of improvement in nonalcoholic fatty liver disease.
    Mazzini GS; Khoraki J; Browning MG; Campos GM
    Cell Death Dis; 2018 Mar; 9(3):354. PubMed ID: 29500352
    [No Abstract]   [Full Text] [Related]  

  • 2. Use of farnesoid X receptor agonists to treat nonalcoholic fatty liver disease.
    Sanyal AJ
    Dig Dis; 2015; 33(3):426-32. PubMed ID: 26045279
    [TBL] [Abstract][Full Text] [Related]  

  • 3. MicroRNA-194 inhibition improves dietary-induced non-alcoholic fatty liver disease in mice through targeting on FXR.
    Nie H; Song C; Wang D; Cui S; Ren T; Cao Z; Liu Q; Chen Z; Chen X; Zhou Y
    Biochim Biophys Acta Mol Basis Dis; 2017 Dec; 1863(12):3087-3094. PubMed ID: 28951211
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Farnesoid X receptor targeting to treat nonalcoholic steatohepatitis.
    Adorini L; Pruzanski M; Shapiro D
    Drug Discov Today; 2012 Sep; 17(17-18):988-97. PubMed ID: 22652341
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Obeticholic acid for the treatment of nonalcoholic steatohepatitis: Expectations and concerns.
    Polyzos SA; Kountouras J; Mantzoros CS
    Metabolism; 2020 Mar; 104():154144. PubMed ID: 31930974
    [No Abstract]   [Full Text] [Related]  

  • 6. Gene expression profiling in human precision cut liver slices in response to the FXR agonist obeticholic acid.
    Ijssennagger N; Janssen AWF; Milona A; Ramos Pittol JM; Hollman DAA; Mokry M; Betzel B; Berends FJ; Janssen IM; van Mil SWC; Kersten S
    J Hepatol; 2016 May; 64(5):1158-1166. PubMed ID: 26812075
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Effects of Farnesoid X Receptor Activation on Arachidonic Acid Metabolism, NF-kB Signaling, and Hepatic Inflammation.
    Gai Z; Visentin M; Gui T; Zhao L; Thasler WE; Häusler S; Hartling I; Cremonesi A; Hiller C; Kullak-Ublick GA
    Mol Pharmacol; 2018 Aug; 94(2):802-811. PubMed ID: 29743187
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Is obeticholic Acid the solution to nonalcoholic steatohepatitis?
    Wong VW; Wong GL; Chan FK
    Gastroenterology; 2015 Apr; 148(4):851-2. PubMed ID: 25726736
    [No Abstract]   [Full Text] [Related]  

  • 9. Obeticholic acid and resveratrol in nonalcoholic fatty liver disease: all that is gold does not glitter, not all those who wander are lost.
    Musso G
    Hepatology; 2015 Jun; 61(6):2104-6. PubMed ID: 25753820
    [No Abstract]   [Full Text] [Related]  

  • 10. MicroRNA-122 Inhibits Lipid Droplet Formation and Hepatic Triglyceride Accumulation via Yin Yang 1.
    Wu GY; Rui C; Chen JQ; Sho E; Zhan SS; Yuan XW; Ding YT
    Cell Physiol Biochem; 2017; 44(4):1651-1664. PubMed ID: 29216638
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Nonalcoholic fatty liver disease: another leap forward.
    Abdelmalek MF
    Nat Rev Gastroenterol Hepatol; 2021 Feb; 18(2):85-86. PubMed ID: 33420415
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Superior reductions in hepatic steatosis and fibrosis with co-administration of a glucagon-like peptide-1 receptor agonist and obeticholic acid in mice.
    Jouihan H; Will S; Guionaud S; Boland ML; Oldham S; Ravn P; Celeste A; Trevaskis JL
    Mol Metab; 2017 Nov; 6(11):1360-1370. PubMed ID: 29107284
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Trials of obeticholic acid for non-alcoholic steatohepatitis.
    Musso G; Cassader M; Gambino R
    Lancet; 2015 Jul; 386(9988):27. PubMed ID: 26169860
    [No Abstract]   [Full Text] [Related]  

  • 14. Trials of obeticholic acid for non-alcoholic steatohepatitis.
    Armstrong MJ; Newsome PN
    Lancet; 2015 Jul; 386(9988):28. PubMed ID: 26169862
    [No Abstract]   [Full Text] [Related]  

  • 15. Treatment Strategies for Nonalcoholic Fatty Liver Disease and Nonalcoholic Steatohepatitis.
    Golabi P; Bush H; Younossi ZM
    Clin Liver Dis; 2017 Nov; 21(4):739-753. PubMed ID: 28987260
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Emerging Treatments for Nonalcoholic Fatty Liver Disease and Nonalcoholic Steatohepatitis.
    Gawrieh S; Chalasani N
    Clin Liver Dis; 2018 Feb; 22(1):189-199. PubMed ID: 29128056
    [TBL] [Abstract][Full Text] [Related]  

  • 17. NAFLD: obeticholic acid for the treatment of fatty liver disease--NASH no more?
    Ray K
    Nat Rev Gastroenterol Hepatol; 2015 Jan; 12(1):1. PubMed ID: 25421586
    [No Abstract]   [Full Text] [Related]  

  • 18. Starting the battle to control non-alcoholic steatohepatitis.
    Ratziu V
    Lancet; 2015 Mar; 385(9972):922-4. PubMed ID: 25468161
    [No Abstract]   [Full Text] [Related]  

  • 19. FXR controls CHOP expression in steatohepatitis.
    Fuchs CD; Claudel T; Scharnagl H; Stojakovic T; Trauner M
    FEBS Lett; 2017 Oct; 591(20):3360-3368. PubMed ID: 28895119
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Trials of obeticholic acid for non-alcoholic steatohepatitis - Authors' reply.
    Neuschwander-Tetri BA; Van Natta ML; Tonascia J; Brunt EM; Kleiner DE
    Lancet; 2015 Jul; 386(9988):28-29. PubMed ID: 26169861
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 6.